Psychological or physical stress induces an elevation of corticosteroids in the circulating system. We report here that corticosterone (CT) protects cardiomyocytes from apoptotic cell death induced by doxorubicin (Dox), an antineoplastic drug known to induce cardiomyopathy possibly through reactive oxygen species production. The cytoprotection induced by CT is within the range of physiologically relevant doses. The lowest dose tested, 0.1 M (or 3.5 g/dl), inhibited apoptosis by approximately 25% as determined by caspase activity. With 1 M CT, cardiomyocytes gain a cytoprotective effect after 8 h of incubation and remain protected for at least 72 h. Hydrocortisone, cortisone, dexamethasone, and aldosterone but not androstenedione or cholesterol also induced cytoprotection. Analyses of 20,000 gene expression sequences using Affymetrix high-density oligonucleotide array found that CT caused up-regulation of 140 genes and down-regulation of 108 genes over 1.5-fold. Among the up-regulated genes are bcl-xL, metallothioneins, glutathione peroxidase-3, and glutathione Stransferases. Western blot analyses revealed that CT induced an elevation of bcl-xL but not bcl-2 or proapoptotic factors bax, bak, and bad. Inhibiting the expression of bcl-xL reduced the cytoprotective effect of CT. Our data suggest that CT induces a cytoprotective effect on cardiomyocytes in association with reprogramming gene expression and induction of bcl-xL gene.
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Stress is known to increase the level of corticosteroids in the circulating system. In humans and rodents, 1 min of psychological stress can increase the plasma corticosteroid levels by 5-to 6-fold. The neuroendocrine cascade hypothesis explains such an increase as a result of hippocampus stimulation, which in turn signals the hypothalamus to produce arginine vasopressin and corticotrophin-releasing factor, either of which can act on the anterior pituitary, causing the release of adrenocorticotropin. Adrenocorticotropin stimulates the adrenal cortex to produce corticosteroids. The major biological form of stress-induced corticosteroid is cortisol in humans and corticosterone (CT) in rodents (Guyton and Hall, 2000) .
The biological function of corticosteroids has been debated over a long period. Early studies found that increased corticosteroid levels caused by long-term stress contributed to memory loss, learning disability, and damage of the hippocampus (Angelucci, 2000) . Although it remains questionable whether corticosteroids damage the hippocampus, it is clear that the level of circulating corticosteroids increases with aging and Alzheimer patients have significantly elevated levels of cortisol in the ventricular cerebrospinal fluid (Angelucci, 2000) . Long-term elevation of corticosteroids contributes to a number of psychiatric disorders, including posttraumatic stress disorder, depression, and dementia. In addition to the neurological impact, prolonged exposure to corticosteroids suppresses immune responses and renders individuals more susceptible to infection and inflammation.
Despite these apparent noxious effects, corticosteroids induce the expression of gluconeogenic enzymes in the liver, the end result of which is increased fatty acid synthesis and energy storage (Guyton and Hall, 2000) .
Synthetic corticosteroids have been used as pharmacological agents in several clinical applications. A few examples of synthetic forms include cortisone, dexamethasone, prednisone, and methylprednisolone. These steroids are currently used in the clinic for treatment of asthma, rheumatoid arthritis, and osteoarthritis as well as for suppression of the immune response during organ transplantation. In spite of the vast amount of information available on corticosteroid function and application, the specific effect of these steroids on the heart has not been thoroughly studied, as evidenced by the limited literature in this area.
Recent literature indicates a role of apoptosis in heart failure and various forms of heart disease (Kang and Izumo, 2000; Chen and Tu, 2002) . Apoptotic-like cell death is known to play a role in cardiomyopathy induced by the antineoplastic drug doxorubicin (Dox) (Keizer et al., 1990; Singal et al., 2000) . Dox is an anthracycline quinone frequently used for treatment of several types of cancer, including breast cancer and leukemia. Although Dox can be an effective antineoplastic drug, its side effect of cardiac toxicity somewhat limits its use (Keizer et al., 1990; Singal et al., 2000) . The administration protocol has been improved to minimize acute cardiac toxicity. However, chronic cardiac toxicity usually develops 2 to 10 years after the drug administration, when patients can show signs of dilated cardiomyopathy, in which apoptoticlike cell death is detectable in a significant proportion of cardiomyocytes during pathological analysis of the failing hearts (Keizer et al., 1990; Singal et al., 2000) . Dox can accept electrons from oxoreductive enzymes in the mitochondria to form semiquinone free radicals, which can initiate a chain of redox reactions. Experimental data have indicated that Dox causes formation of superoxide and H 2 O 2 when it is incubated with the mitochondrial fraction of heart extracts (Doroshow and Davies, 1986) . In addition to inducing oxidative stress, Dox at high concentrations can interact with DNA topoisomerase, be intercalated into DNA, and cause DNA strand breaks (Singal et al., 2000) . At the cellular level, Dox has often been used as a model compound for inducing apoptosis in a number of cell types, including cardiomyocytes. This provides us with an experimental system to test the effect of corticosteroids on apoptosis induced by Dox in cardiomyocytes.
Materials and Methods
Chemicals. All chemicals or drugs were obtained from SigmaAldrich (St. Louis, MO) unless otherwise indicated in the text.
Cell Culture and Treatment of Drugs. Cardiomyocytes were prepared from 1-to 2-day-old neonatal Sprague-Dawley rats (Harlan, Indianapolis, IN) as described previously (Coronella-Wood et al., 2004) . The myocytes were seeded at a density of 2 ϫ 10 6 cells per 100-mm dish, 0.3 ϫ 10 6 cells per well of six-well plates, or 7.5 ϫ 10 4 cells per well of 24-well plates. At 3 to 4 days after plating, cardiomyocytes were cultured in DMEM containing 0.5% fetal bovine serum and CT at 1 M or indicated doses. At 1 to 3 days after culture with corticosteroids, media were changed to fresh DMEM containing 0.5% fetal bovine serum, and Dox was added to a final concentration of 1 M for 20-to 24-h incubation unless otherwise indicated.
Caspase Activity Assay. Detached cells were collected by centrifugation and were mixed with adherent cells from the same well in six-well plates. The combined cells were dissolved in 200 l of lysis buffer (0.5% Nonidet P-40, 0.5 mM EDTA, 150 mM NaCl, and 50 mM Tris, pH 7.5) for measurements of caspase-3 activity using 40 M N-acetyl- methylcoumarin (Nacetyl-DEVD-AMC; Alexis Biochemicals, San Diego, CA). The released AMC was measured as the relative fluorescence unit using a 96-well fluorescence plate reader (Spectra Max; Molecular Devices, Sunnyvale, CA) with an excitation wavelength of 365 nm and an emission wavelength of 450 nm.
Annexin V Binding Assay. Cells were seeded onto coverglasses in 24-well plates. Detached cells in the supernatant were collected by 5-min centrifugation at 1000 rpm (500g). After washing the detached cells and adherent cells with phosphate-buffered saline separately, detached cells were combined with their corresponding group of cells remained adherent to the coverglass after addition of the labeling solution (10 mM HEPES/NaOH, pH 7.4, 140 mm NaCl, and 5 mM CaCl 2 ). Annexin V-FLOUS (Roche Diagnostics, Indianapolis, IN) was added to the sample (25 l per well). The cells were examined under a Nikon E800m fluorescent microscope (Nikon, Tokyo, Japan), and the images were acquired using a Hamamatsu C5180 digital camera (Hamamatsu Corporation, Bridgewater, NJ) with the Adobe Photoshop software (Adobe Systems, Mountain View, CA).
MTT Assay for Cell Viability. At the end of Dox or CT plus Dox treatment, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich) was added to cells in six-well plates to 0.5 mg/ml in culture medium. After 20-min incubation in a 37°C tissue culture incubator, culture medium was removed, and the resulting formazan crystals were dissolved in isopropanol. The solublized formazan products were quantified by a spectrophotometer (1601; Shimadzu, Kyoto, Japan) for absorbance at a wavelength of 570 nm. The background absorbance was subtracted by spectrophotometric measurements at a wavelength 690 nm.
Western Blot. Cells in 100-mm dishes were lysed by scraping in EB buffer (for glucocorticoid receptors, 1% Triton X-100, 10 mM Tris, pH 7.4, 5 mM EDTA pH 8.0, 50 mM NaCl, 50 mM NaF, and 2 mM Na 3 VO 3 ) or Laemmli buffer [for bcl-2 or bcl-xL, 0.5 M Tris, pH 6.8, 2.4% (w/v) SDS, and 50% (v/v) glycerol] with freshly added protease inhibitors (Coronella-Wood et al., 2004) . Protein concentration was measured by the Bradford method (Bio-Rad, Hercules, CA), the bicinchoninic acid method (Pierce Chemical, Rockford, IL), or the Warburg-Christian method (Layne, 1957) . Proteins were separated by SDS-polyacrylamide gel electrophoresis and were transferred to Immobilon-P membranes (Millipore, Bedford, MA). The membrane was incubated with antibodies obtained from Cell Signaling Technology Inc. (Beverly, MA) against cytochrome c or caspase-3; from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA) against caspase-3, glucocorticoid receptor, Bcl-xL, cyclin B1, cyclin D1, bcl-2, bax, or bak; from Sigma-Aldrich against ␣-smooth muscle actin, proliferating cell nuclear antigen, or vinculin; from Calbiochem (San Diego, CA) against glutathione S-transferase (GST)␣1 or GSTmu2; from Cayman Chemical (Ann Arbor, MI) against cyclooxygenase-2 (Cox-2) and Cox-1; from Stressgen Biotechnologies (San Diego, CA) against heat shock protein 27 (Hsp27); or from MBL International (Woburn, MA) against Bad. The bound antibodies were detected using an enhanced chemiluminescence reaction after blotting with the secondary antibodies conjugated with horseradish peroxidase.
Microarray. Cardiomyocytes were harvested by TRIzol (SigmaAldrich) for extraction of total RNA. RNA was cleaned with an RNeasy mini kit (QIAGEN, Valencia, CA). The quality of RNA was examined by agarose gel electrophoresis and the Agilent 2100 bioanalyzer (Agilent Technologies, Palo Alto, CA) to ensure the purity and integrity of RNA suitable for microarray. The RNA was converted to cDNA by reverse transcription using the SuperScript Choice kit from Invitrogen (Carlsbad, CA) with a T7-(dT)24 primer incorporating a T7 RNA polymerase promoter. The cRNA was prepared and labeled with biotin via in vitro transcription using the Enzo bioarray high-yield RNA transcript labeling kit (Enzo Biochemical, Farmingdale, NY). Labeled cRNA was fragmented by incubation at 94°C for 35 min. For hybridization, 15 g of fragmented cRNA was incubated for 16 h at 45°C with a Rat Expression 230A Gene chip. After hybridization, the gene chips were automatically washed and stained with streptavidin-phycoerythrin using a fluidics station (Affymetrix, Santa Clara, CA). The probed arrays were scanned at 3-m resolution using the Genechip System confocal scanner RT-PCR. Total RNA extracted using TRIzol was used as templates for RT-PCR. Moloney murine leukemia virus reverse transcriptase (Invitrogen) was used for reverse transcription at 37°C for 90 min. The denaturation and primer extension temperature was 94 and 72°C, respectively. The annealing temperature varied depending on the GC content of the primers as suggested by the oligonucleotide synthesis company (Bio-Synthesis, Lewisville, TX). The primer sequences are 5Ј-AGGCTGGCGATGAGTTTGAA and 5Ј-CGGCTC-TCGGCTGCTGCATT for bcl-xL, 5Ј-GAATTCCGTTGCTCCAGAT-TCACCAGATC and 5Ј-GAATTCTCACATGCTCGGTAGAAAACGG for metallothionein I, 5Ј-AAACAGGAGCCAGGCGAGAACT and 5Ј-CCCGTTCACATCTCCTTTCTCAAA for glutathione peroxidase-3, 5Ј-CCCTGAGAACCAGAGTCAGC and 5Ј-CCCAGCAATTCCTCAT-CAGT for GST␣1, 5Ј-ATTCGCCTGTTCCTGGAGTA and 5Ј-AAA-CGTCCACACGAATCCTC for GSTmu2, 5Ј-TTTTTTTTCCCAAC-CCTTGC and 5Ј-AATGAACAAAGGTTGGGGGG for serum/glucocorticoid-regulated kinase (SGK), 5-AAAGCTTGTCACTGGGGC-CAGCAAA and 5Ј-AGGATCCAGAGCAAACTTGCTTGCA for hydroxysteroid 11␤ dehydrogenase 1 (11␤-HSD), 5Ј-GAGACCCTGT-GCGTGATTGC and 5Ј-CCTGCTCCACCTGGCTGAGG for adrenergic receptor ␤2 (␤2-AR), 5Ј-TACAAGCAGTGGCAAAGGCC and 5Ј-CAGTATTGAGGAGAACAGATGGG for Cox-2, 5Ј-TAAGTACCA-GGTGCTGGATGG and 5Ј-GGTTTCCCCTATAAGGATGAG for Cox-1, 5Ј-GGAGACGACTTACAGTGTAGCC and 5Ј-CACACCCAA-AGCAATCTTC for angiotensin-converting enzyme 1 (ACE1), 5Ј-GAAATACACGCTCCCTCCAG and 5Ј-GGCTTCTACTTGGCTCC-AGA for Hsp27, and 5Ј-AGACAGCCGCATCTTCTTGT and 5Ј-CC-ACAGTCTTCTGAGTGGCA for glyceraldehyde-3-phosphate dehydrogenase. The products were detected by agarose gel electrophoresis and ethidium bromide staining.
Bcl-xL siRNA Transfection. Primary cultured cardiomyocytes were transfected with siRNA on the third day of plating. The cells in six-well plates were incubated 6 h with 100 nM each 5Ј-GGCUGGCGAUGAGUUUGAAtt-3Ј (abbreviated as SI; Ambion, Austin, TX) and 5Ј-GGUAGUGAAUGAACUCUUUtt-3Ј (abbreviated as SII; Ambion) or a silencer negative control small interference RNA (siRNA) of 19-base oligonucleotide derived from a scrambled sequence (Ambion) in a 1-ml mixture of Opti-MEM (Invitrogen) and DMEM containing 3 l of Oligofectamine (Invitrogen). At 48 h after transfection, cells were treated with corticosterone for determining the protein level of bcl-xL and the effect of corticosterone on Dox-induced apoptosis.
Results

Corticosterone Inhibits Apoptosis Induced by Dox.
Cardiomyocytes are adherent cultures, but they detach and round up when they undergo apoptosis. Such morphology was observed with the treatment of Dox at 1 M or higher doses. Caspase-3 activity measurement was used as a quantitative assay for apoptosis. When cardiomyocytes were incubated with Dox for 24 h, an elevated activity of caspase-3 was observed with Dox at 0.1 M or above (Fig. 1 ). Caspase-3 activity assay indicates that 1.0 M was an appropriate dose for inducing apoptosis because a higher dose (5.0 M) did not seem to induce more caspase-3 activity (Fig. 1A) . Activation of caspase-3 by Dox was detectable at 9 h but reached the highest level at 24 h (Fig. 1B) .
The vast amount of literature concerning CT involves induction of apoptosis in lymphocytes and neuronal cells. We have tested whether CT could induce apoptosis in cardiomyocytes. Our experiments failed to show that CT induced apoptosis in cardiomyocytes using physiologically relevant doses (0.1 M or 3.5 g/dl to 1 M or 35 g/dl) or higher (1-100 M). To test the effect of CT on Dox-induced apoptosis, cardiomyocytes were cultured in medium containing 1.0 M CT for 3 days and were placed in fresh medium afterward for Dox treatment. Figure 1B shows that cells cultured with CT were reluctant to activate caspase-3 as evidenced by measurements at various times after Dox treatment. The effect of CT was dose-dependent and the lowest dose tested, 0.1 M, showed approximately 25% protective effect (Fig.  1C ). CT at 1 M can inhibit approximately 70% of caspase-3 activity induced by Dox (Fig. 1C) .
Morphological analysis was consistent with caspase-3 mea- Fig. 2, I and J). Scoring the percentage of cells that round up and detach or exhibit the nuclear morphology of apoptotic cells provided quantitative evidence that CT pretreatment indeed inhibits Dox from inducing apoptotic-like cell death (Fig. 2K ). To demonstrate that CT indeed prevented the loss of cell viability induced by Dox, we measured cell viability using MTT assay. Figure 2L shows that whereas Dox caused reduction in cell viability, treatment of CT prevented the loss of cell viability. Additional evidence supporting CT inhibition of apoptosis was shown with the DNA degradation assay (Fig. 3A) , loss of mitochondrial cytochrome c (Fig. 3B) , and caspase-3 cleavage (Fig. 3C ). Cell death can be induced by a number of damaging agents. To address whether CT inhibits apoptosis induced by chemicals in addition to Dox, we tested the effect of CT on caspase-3 activated by two other cardiac toxins: palmitate and 2-deoxyglucose (De Windt et al., 2000; Hickson-Bick et al., 2002) . Although it is not clear whether oxidative stress ) were collected for staining of nuclei with low concentration of propidium iodine (1.0 g/ml) as described in . The percentage of cells floated into the medium or the percentage nuclei showed nuclear condensation or fragmentation (K) was scored under a microscope as described previously . For cell viability assay (L), MTT was added to cells for 20-min incubation as described under Materials and Methods, and the data of absorbance represent mean Ϯ S.D. from three independent experiments. Fig. 3 . Assays of DNA degradation, mitochondrial loss of cytochrome c, and cleavage of caspase-3 support that CT induces cytoprotection. Cardiomyocytes were cultured in DMEM containing 1 M CT for 3 days. The cells were placed in fresh medium and treated 24 h with 1 M Dox for measurement of DNA degradation (A) by agarose gel electrophoresis after extracting genomic DNA as described previously (Chen et al., 1995) plays a role in palmitate or 2-deoxyglucose toxicity, these two compounds induced activation of caspase-3 at 0.5 and 25 mM doses, respectively (Fig. 4A) . Pretreatment with CT prevented palmitate or glutamate from inducing caspase-3 activation (Fig. 4A) , suggesting that CT may protect cardiomyocytes from cell death induced by a number of toxins.
We then tested the effect of several different corticosteroids on caspase-3 activation induced by Dox to determine whether the inhibition of apoptosis is limited to CT. Among the steroids tested, hydrocortisone, dexamethasone, cortisone, and aldosterone showed an inhibitory effect against Dox-induced caspase-3 activation (Fig. 4B) . 4-Androstenedione, an intermediate of steroid synthesis, and cholesterol, the precursor of adrenal steroids, failed to inhibit caspase-3 activation (Fig. 3B) .
Delayed Time Course and Dependence on Receptor and Protein Synthesis. To determine the mechanism of CT-induced cytoprotection, we tested the role of the glucocorticoid receptor (GR) (Yudt and Cidlowski, 2002) . Rat neonatal cardiomyocytes express GR, and the two protein bands from Western blot analyses represent the 94-kDa ␣ isoform and 90-kDa ␤ isoform (Fig. 5A) . Treatment of CT did not seem to alter the level of GRs (Fig. 5A ). Mifepristone (MF) can bind to GR with high affinity and maintains the receptor in an inappropriate conformation for corticosteroid binding (Cadepond et al., 1997) . We tested the effect of MF on CT-induced cytoprotection by pretreating cells with MF for 30 min before CT addition. It was found that CT in the presence of MF could no longer inhibit caspase-3 activation induced by Dox treatment (Fig. 5B) .
The cytoprotective effect of CT was first discovered by culturing cardiomyocytes with CT for 3 days. To define the minimal time frame required for CT to produce a cell survival response, we pretreated cells with CT from 30 min to 8 h or for 1, 2, and 3 days before Dox treatment. The results showed that 8-h CT pretreatment was starting to have a cytoprotective effect (Fig. 6A) , and 24-h pretreatment was just as effective as 3-day pretreatment in inhibiting apoptosis (Fig. 6B) . The fact that CT requires 8 h or more to induce a cell survival response led us to postulate that new protein synthesis could have played a role. We therefore tested the dependence of new protein synthesis on CT-induced cell survival by placing cells in a medium deficient of the essential amino acids methionine and cysteine or by adding the protein synthesis inhibitor cycloheximide to the complete culture medium during 24-h CT pretreatment. The culture medium was changed back to fresh complete medium during 24-h Dox treatment. In complete medium, CT inhibited 76.2% caspase activity induced by Dox treatment. The methionine-and cysteinedeficient medium reduced CT inhibition to 48.1%. Addition of 0.5 g/ml cycloheximide during CT pretreatment reduced the protective effect down to 20%. The results indicate a role of new protein synthesis in CT-induced cell survival response.
Gene Expression Altered by Corticosteroids. Microarray analysis allows us to systematically address the mechanism of CT-induced cytoprotection without the bias of prior knowledge. We have used the Affymetrix highdensity oligonucleotide expression array system to identify the genes that change expression levels by CT treatment. RNA was harvested from control or treated cardiomyocytes at 24 h after addition of 1 M CT. This time was chosen We examined the expression of 20,000 genes or transcribed sequences using the Rat Expression 230A Gene chips. The results revealed that approximately 1.7% genes changed expression by 1.5-fold or more in cells treated with CT. CT induced 140 genes plus 116 unnamed transcribed sequences to increase their expression more than 1.5-fold. There were 108 genes plus 72 unnamed transcribed sequences down-regulated by CT treatment. The unnamed transcribed sequences have been verified by searching against the Unigene database (http://www.ncbi.nlmr.gov) for gene names and have either no sequence homology or less than 50% homology to a specific gene in the database. Table 1 lists the genes that are up-or down-regulated by CT treatment. We have verified the gene array data by RT-PCR analysis for 12 genes. All of the genes tested by RT-PCR were up-regulated by CT treatment (Fig. 7) . The RT-PCR data are therefore consistent with the microarray finding. Among the up-regulated genes found by microarray analyses are the antiapoptotic gene bcl-xL and several antioxidant, detoxification enzymes and metal binding proteins, including metallothionein I and II, glutathione peroxidase-3, and glutathione S-transferases (Table 1 ). In addition, a number of the genes up-regulated by CT have been shown to contribute to cell survival in the literature, some of which have been shown specifically to be cytoprotective for cardiomyocytes. These genes include insulin like growth factor-1, Hsp27, prostaglandin-endoperoxide synthetase-2 (Cox-2), and SGK (Table 1) . Microarray analyses also revealed that CT induced six muscle or contractile proteins; six channel proteins; four prostaglandin synthesis enzymes; 12 endocrine factors or their binding proteins; six receptors; 15 signaling molecules; eight transcription factors; three chromatin or DNA binding proteins; nine cytoskeletal proteins; seven cell surface or extracellular matrix proteins; and 11 enzymes for energy, nucleic acid, lipid, or steroid metabolism (Table 1) . Although many of the above-mentioned categories also have genes that were down-regulated by CT, the most striking finding among the decreased genes are cell cycle regulators (Table 1) . We have verified the expression of bcl-xL, two GSTs, Cox 1 and 2, Hsp27, cyclin D2, cyclin B1, and proliferating cell nuclear antigen at the protein level by Western blot analyses using commercially available antibodies. Those have been verified by Western blot show consistent results with microarray or RT-PCR analyses in induction or reduction (Fig. 8) . The gene array data suggest that CT induces multiple changes at the gene expression level. A part of these changes probably contribute to the observed cytoprotection as reported here.
Induction of Bcl-xL in Absence of Elevation of Bcl-2 or Proapoptotic Factors. The prosurvival members of the bcl-xL family can protect cells from apoptosis in various experimental systems. An increase in the protein level of bcl-xL could explain the cytoprotection induced by CT pretreatment. To determine the correlation between bcl-xL induction and inhibition of apoptosis, we have measured the dose response and time course of bcl-xL induction. An elevation of bcl-xL protein was observed with 24-h treatment of CT at the concentration of 0.1 M and the elevation reached its highest level with 1.0 M CT (Fig. 9A) . With 1.0 M CT treatment, the elevation was significant at 4 h, reached the highest induction at 8 h, and remained at the highest level of induction throughout 72 h (Fig. 9B) . Treatment with MF abolished induction of bcl-xL by CT (Fig. 9C) . The dose response, time course, and the impact of MF studies suggest that bcl-xL induction correlates well with the cytoprotective effect of CT.
Previous studies found that treatment with Dox can change the level of bcl-xL protein (Negoro et al., 2001) , posing the question of whether induction of bcl-xL indeed contributes to the observed cytoprotective effect of CT. We determined the levels of bcl-xL induction by CT with or without Fig. 7 . RT-PCR verification of increased expression of antiapoptosis, antioxidant, detoxification, and other genes identified by microarray analyses. Cardiomyocytes were treated with 1 M CT for 24 h, and total RNA (2 g) was used for reverse transcription and PCR reaction with primer pairs designed specifically for the metallothionein-I (MT I), glutathione peroxidase-3 (GPx-3), GST␣1, GSTmu2, SGK, 11␤-HSD1, ␤2-AR, Cox-2, Cox-1, ACE1, Hsp27, or glyceraldehyde-3-phosphate dehydrogenase (GADPH). The PCR products were detected by ethidium bromide staining after agarose gel electrophoresis. Alpha Innotech (San Leandro, CA) Image system was used to acquire the images using Adobe Photoshop software. Dox treatment. Figure 10 shows that although the induction of bcl-xL by CT is profound, Dox did not seem to alter the level of bcl-xL significantly in our experimental system within the time frame tested (24 h).
We have used stringent conditions to select for genes that were up-or down-regulated by CT treatment during microarray analyses. Target measurements of genes in the bcl-2 family allow us to determine the importance of bcl-xL elevation in CT-induced cytoprotection. Bcl-2 is another prosurvival factor, overexpression of which can protect cells from undergoing apoptosis. Measurement of bcl-2 protein revealed that CT or Dox did not induce significant changes in the level of bcl-2 protein (Fig. 10) . Bcl-xL can dimerize with the proapoptotic factors bax and bak and prevent these proapoptotic factors from releasing mitochondrial cytochrome c. Bad, another proapoptotic factor, can inhibit the action of bcl-xL. Down-regulation of these proapoptotic factors could contribute to cytoprotection. To test this possibility, we have determined the level of bax, bak, and bad proteins in CT-treated cells with or without Dox treatment. The results show that CT or Dox treatment did not seem to alter the level of these proapoptotic protein factors within the time frame tested (Fig. 10) .
To determine the contribution of bcl-xL induction in CTinduced cytoprotection, we have used siRNA to inhibit the expression of bcl-xL. Measurements of bcl-xL level after transfecting a combination of two siRNAs showed the retardation of bcl-xL induction by CT treatment (Fig. 11A) . Measurements of caspase-3 activity at 16 h after Dox treatment indicated that bcl-xL siRNA abolished CT-mediated cytoprotection. Scoring the percentages of cells detached or showing nuclear condensation or nuclear fragmentation at 24 h after Dox treatment revealed that bcl-xL siRNAs partially reversed the cytoprotective effect of CT (Fig. 11, B and C) . These data suggest that induction of bcl-xL contributes to the cytoprotective effect of CT.
Discussion
This study revealed that CT inhibits apoptotic-like cell death induced by Dox in primary cultured cardiomyocytes.
The dose range found to inhibit cell death in this study is 0.1 to 100 M. The lowest dose tested here (i.e., 0.1 M or 3.5 g/dl) is related to the basal level of cortisol in the circulating system of humans (2-5 g/dl). The concentration of CT relevant to the circulating level of cortisol in human during stress (0.7-1 M) seemed to be optimal in inducing cytoprotection. Therefore, this finding may contribute to understanding the physiological impact of stress on the heart in humans.
Recent studies have demonstrated the presence of apoptotic cells in biopsy samples of failing human hearts and in the myocardium of experimental animals with failing hearts (Kang and Izumo, 2000; Chen and Tu, 2002) . There is evidence that inhibiting apoptosis may alleviate certain clinical manifestations of heart failure in experimental animals (Feuerstein et al., 1998; Ma et al., 1999; Kotamraju et al., 2000) . Dox is known to induce dilated cardiomyopathy. The presence of a large amount of apoptotic cells in the myocardium of Dox-treated patients has been traditionally thought to contribute to the dilated cardiomyopathy and heart failure (Keizer et al., 1990; Singal et al., 2000) . Therefore, inhibitors of apoptosis may provide hope for the prevention or treatment of Dox-induced cardiomyopathy.
One caveat is the potential difference of corticosteroid effects in vitro versus in vivo. The clinical impact of corticosteroids on the heart has been an issue under intensive debate (Ng and Celermajer, 2004) . In general, physicians tend not to prescribe corticosteroids to patients with cardiovascular disease because of potential detrimental effects of the steroids on electrophysiology of the heart and on the vascular system. Earlier clinical observations indicate that administration of dexamethasone causes sudden cardiac arrhythmias (Schmidt et al., 1972; Rao et al., 1972) . In addition, corticosteroids have been found to increase the peripheral vascular resistance and cause increases in blood pressure in a dose-dependent manner (Kelly et al., 1998; Whitworth et al., 2001) . Prolonged overexposure to corticosteroids can cause Cushing's syndrome, a rare disease manifested by depression, osteoporosis, diabetes, and high blood pressure. In agreement with these unwanted effects, our microarray analyses show that CT induces the expression of ␤2-AR, which may affect the contractility and therefore arrhythmias of the heart. We also found that CT induces the expression of ACE1, which may result in an increased production of angiotensin II, a peptide known to contribute to cardiac hypertrophy and heart failure. The enzyme 11␤-HSD converts 11-keto-steroids into active glucocorticoids and therefore amplifies the action of glucocorticoids. Despite these undesirable effects in vivo and in vitro, corticosteroids have been found to protect the heart from ischemia and reperfusion injury in animal models (Libby et al., 1973; Spath et al., 1974; Busuttil and George, 1978; Valen et al., 2000) . Whether corticosteroids can initiate an antiapoptotic response in vivo in mediating the cardiac protective effect remains to be investigated.
The discovery of bcl-xL elevation provides one answer to the observed antiapoptotic effect of CT. The time course of bcl-xL elevation seems to be consistent with the long lag time (i.e., 8 h) required for cells to gain antiapoptotic ability and with the dependence of new protein synthesis for CT-induced cytoprotection. The balance of prosurvival factors versus proapoptotic factors in the bcl-2 family seems to be tipped toward the prosurvival side with the induction of bcl-xL, because no increase of proapoptotic factors bax, bak, and bad was observed with CT treatment. In certain experimental systems of chemical-induced apoptosis, increases in bax, bak, or bad have been observed. Bax, bak, or bad can form channels on the mitochondrial membrane for cytochrome c release when levels of these proapoptotic proteins are elevated or when they escape from the surveillance of their inhibitors, such as bcl-2 and bcl-xL. With Dox treatment alone, we did not observe an increase in the levels of bax, bak, or bad (Fig.  10) . However a loss of mitochondrial cytochrome c was observed with Dox treatment (Fig. 3B) , suggesting the possibility of mitochondrial membrane permeability transition in mediating cytochrome c release. Dox has been shown to produce reactive oxygen species (Doroshow and Davies, 1986; Keizer et al., 1990; Singal et al., 2000) . Oxidants can induce mitochondrial membrane permeability transition, which is typically triggered by increases in cytosolic Ca 2ϩ (Takeyama et al., 1993; Kuwana and Newmeyer, 2003) . The endoplasmic reticulum (ER) plays a critical role in regulating the concentration of cytosolic Ca 2ϩ . Recent evidence indicates that bcl-2 regulates the level of cytosolic Ca 2ϩ through its ER localization (Kuwana and Newmeyer, 2003; Annis et al., 2004) . Bcl-xL has also been found to locate in the ER in addition to its mitochondrial and cytosolic distribution (Annis et al., 2004) . This suggests the possibility that bcl-xL may prevent apoptosis through inhibiting mitochondrial membrane permeability transition. However, we cannot exclude the possibility that Dox, without increasing the level of bax, bak, or bad, inactivates the surveillance of bax, bak, or bad, causing cytochrome c release through formation of mitochondrial membrane channels. CT enhances the surveillance by inducing bcl-xL, which inhibits the formation of mitochondrial cytochrome c release channel by bax, bak, and bad. Regardless, inhibiting the expression of bcl-xL using siRNAs proved the role of bcl-xL in the CT-induced antiapoptotic effect. The bcl-xL gene has been shown to be induced by a number of stimuli, such as UV irradiation, cytokines, and chemical stress (Grad et al., 2000) . The elevated expression of bcl-xL can be regulated at transcriptional levels. The promoter region of the bcl-xL gene contains consensus-binding sites for Rel/nuclear factor-B, Ets, and signal transducer and activator of transcription transcription factors. There is evidence that GR transcription factor can cross-talk with STAT-3 in regulating bcl-xL gene expression (Takeda et al., 1998) .
Microarray analyses indicated that CT induces a multitude of changes at the gene expression level. Transcriptional regulation has been a main feature studied in the biology of corticosteroids (Karin, 1998; Adcock, 2001) . Upon binding to corticosteroids, GR transforms from a silent to an active transcription factor. GR forms a homodimer that binds to the glucocorticoid response element (GRE) in the promoter region of target genes, resulting in transcriptional activation of these genes. Metallothionein I, a metal binding protein that has been shown to function as an antioxidant and protect cardiomyocytes from Doxinduced toxicity in vitro and in vivo (Kang, 1999; Sun et al., 2001) , contains GRE in its promoter (Karin, 1998) . Consistent with the literature, CT indeed induced the expression of metallothionein I in cardiomyocytes as indicated in our microarray and RT-PCR analysis. In addition to activating the transcription of genes containing the GRE in their promoter, corticosteroids have been shown to regulate transcription through chromatin remodeling and to repress transcription of genes containing a negative GRE cis-element in their promoters (Bamberger et al., 1996; Adcock, 2001; Deroo and Archer, 2001) . CT can also bind to an orphan receptor, the pregnane X receptor (PXR) (Xie and Evans, 2001 ). Activation of PXR composes a novel steroid signaling and transcriptional regulation pathway that is distinct from the classic glucocorticoid receptormediated pathways. PXR knockout mice are hypersensitive to the toxicity of xenobiotics (Xie and Evans, 2001) , suggesting a role of PXR in cytoprotection. These pieces of evidence in conjunction with our microarray data suggest that CT treatment can reprogram the gene expression profile in cardiomyocytes. Although induction of bcl-xL may contribute to cell survival, it seems unlikely that the observed cytoprotection induced by CT in cardiomyocytes is associated with one gene not the others. Changes in 1.7% of genes from the cardiomyocyte genome depict the state of CT-treated cells. 
